AR116695A1 - Los neuroesteroides y sus métodos de uso - Google Patents
Los neuroesteroides y sus métodos de usoInfo
- Publication number
- AR116695A1 AR116695A1 ARP190102913A ARP190102913A AR116695A1 AR 116695 A1 AR116695 A1 AR 116695A1 AR P190102913 A ARP190102913 A AR P190102913A AR P190102913 A ARP190102913 A AR P190102913A AR 116695 A1 AR116695 A1 AR 116695A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- ora1
- hydrogen
- sra1
- Prior art date
Links
- 239000002858 neurotransmitter agent Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 101000743846 Diplobatis ommata Ras-related protein Rab-10 Proteins 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 8
- 150000002431 hydrogen Chemical group 0.000 abstract 8
- 125000000304 alkynyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 101000829425 Homo sapiens Steroid receptor RNA activator 1 Proteins 0.000 abstract 6
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 abstract 6
- 102100023706 Steroid receptor RNA activator 1 Human genes 0.000 abstract 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 6
- 102000016304 Origin Recognition Complex Human genes 0.000 abstract 4
- 108010067244 Origin Recognition Complex Proteins 0.000 abstract 4
- 101150007570 nra-1 gene Proteins 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 239000011593 sulfur Substances 0.000 abstract 4
- 101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 abstract 3
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este; caracterizado porque: ⁻ ⁻ ⁻ ⁻ ⁻ ⁻ representa un enlace simple o doble, siempre que exista un enlace doble, entonces no hay uno de R⁶ᵃ o R⁶ᵇ; R¹ es hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -ORA¹, -N(RA¹)₂, -SRA¹, -C(=O)RA¹; -C(=O)ORA¹, -C(=O)SRA¹, -C(=O)N(RA¹)₂, -OC(=O)RA¹, -OC(=O)ORA¹, -OC(=O)N(RA¹)₂, -OC(=O)SRA¹, -OS(=O)₂RA¹, -OS(=O)₂ORA¹, -OS(=O)₂N(RA¹)₂, -N(RA¹)C(=O)RA¹, -N(RA¹)C(=NRA¹)RA¹, -N(RA¹)C(=O)ORA¹, -N(RA¹)C(=O)N(RA¹)₂, -N(RA¹)C(=NRA¹)N(RA¹)₂, -N(RA¹)S(=O)₂RA¹, -N(RA¹)S(=O)₂ORA¹, -N(RA¹)S(=O)₂N(RA¹)₂, -SC(=O)RA¹, -SC(=O)ORA¹, -SC(=O)SRA¹, -SC(=O)N(RA¹)₂, -S(=O)₂RA¹, -S(=O)₂ORA¹, o -S(=O)₂N(RA¹)₂, caracterizado porque cada caso de RA¹ se selecciona independientemente del hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, un grupo de protección de oxígeno cuando se une al oxígeno, un grupo de protección de nitrógeno cuando se une al nitrógeno, un grupo de protección de azufre cuando se une al azufre, o dos grupos de RA¹ se toman con los átomos intermedios para formar un anillo heterocíclico sustituido o no sustituido; cada uno de R²ᵃ, R²ᵇ, R⁴ᵃ, R⁴ᵇ, R⁷ᵃ, R⁷ᵇ, R¹¹ᵃ, R¹¹ᵇ, R¹²ᵃ, R¹²ᵇ y R¹⁷ᵇ, son independientemente hidrógeno, halógeno, -CN, -NO₂, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -ORA¹, -N(RA¹)₂, -SRA¹, -C(=O)RA¹, -C(=O)ORA¹, -C(=O)SRA¹, -C(=O)N(RA¹)₂, -OC(=O)RA¹, -OC(=O)ORA¹, -OC(=O)N(RA¹)₂, OC(=O)SRA¹, -OS(=O)₂RA¹, -OS(=O)₂ORA¹, -OS(=O)₂N(RA¹)₂, -N(RA¹)C(=O)RA¹, -N(RA¹)C(=NRA¹)RA¹, -N(RA¹)C(=O)ORA¹, -N(RA¹)C(=O)N(RA¹)₂, -N(RA¹)C(=NRA¹)N(RA¹)₂, -N(RA¹)S(=O)₂RA¹, -N(RA¹)S(=O)₂ORA¹, -N(RA¹)S(=O)₂N(RA¹)₂, -SC(=O)RA¹, -SC(=O)ORA¹, -SC(=O)SRA¹, -SC(=O)N(RA¹)₂, -S(=O)₂RA¹, -S(=O)₂ORA¹, o -S(=O)₂N(RA¹)₂, caracterizado porque cada caso de RA¹ se selecciona independientemente del hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, un grupo de protección de oxígeno cuando se une al oxígeno, un grupo de protección de nitrógeno cuando se une al nitrógeno, un grupo de protección de azufre cuando se une al azufre, o dos grupos de RA¹ se toman con los átomos intermedios para formar un anillo heterocíclico sustituido o no sustituido; R³ᵃ es hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido; R⁵ es hidrógeno o metilo; cuando ⁻ ⁻ ⁻ ⁻ ⁻ ⁻ es un enlace doble, R⁵ se ausenta; cada uno de R⁶ᵃ y R⁶ᵇ es hidrógeno, halógeno, -CN, -NO₂, -OH, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido; o R⁶ᵃ y R⁶ᵇ se enlazan para formar un grupo oxo (=O); cada uno de R¹⁵ᵃ, R¹⁵ᵇ, R¹⁶ᵃ y R¹⁶ᵇ son independientemente hidrógeno, halógeno, -CN, -NO₂, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -ORC³, -N(RC³)₂, -SRC³, -C(=O)RC³, -C(=O)ORC³, -C(=O)SRC³, -C(=O)N(RC³)₂, -OC(=O)RC³, -OC(=O)ORC³, -OC(=O)N(RC³)₂, -OC(=O)SRC³, -OS(=O)₂RC³, -OS(=O)₂ORC³, -OS(=O)₂N(RC³)₂, -N(RC³)C(=O)RC³, -N(RC³)C(=NRC³)RC³, -N(RC³)C(=O)ORC³, -N(RC³)C(=O)N(RC³)₂, -N(RC³)C(=NRC³)N(RC³)₂, -N(RC³)S(=O)₂RC³, -N(RC³)S(=O)₂ORC³, -N(RC³)S(=O)₂N(RC³)₂, -SC(=O)RC³, -SC(=O)ORC³, -SC(=O)SRC³, -SC(=O)N(RC³)₂, -S(=O)₂RC³, -S(=O)₂ORC³, o -S(=O)₂N(RC³)₂, caracterizado porque cada caso de RC³ se selecciona independientemente del hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, un grupo de protección de oxígeno cuando se une al oxígeno, un grupo de protección de nitrógeno cuando se une al nitrógeno, un grupo de protección de azufre cuando se une al azufre, o dos grupos de RC³ se toman con los átomos intermedios para formar un anillo heterocíclico sustituido o no sustituido; R¹⁹ es carbociclilo sustituido o no sustituido C₃₋₆ o arilo sustituido o no sustituido; y n es 0, 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745109P | 2018-10-12 | 2018-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116695A1 true AR116695A1 (es) | 2021-06-02 |
Family
ID=68425315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102913A AR116695A1 (es) | 2018-10-12 | 2019-10-11 | Los neuroesteroides y sus métodos de uso |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11634453B2 (es) |
| EP (2) | EP4321519A3 (es) |
| JP (2) | JP7671244B2 (es) |
| CN (2) | CN121045302A (es) |
| AR (1) | AR116695A1 (es) |
| AU (2) | AU2019357040B2 (es) |
| BR (1) | BR112021009428A2 (es) |
| CA (1) | CA3115805A1 (es) |
| DK (1) | DK3864022T3 (es) |
| ES (1) | ES2966055T3 (es) |
| IL (1) | IL282183A (es) |
| MX (2) | MX2021004159A (es) |
| TW (2) | TWI886813B (es) |
| WO (1) | WO2020077255A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59734B1 (sr) | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| CN115974955A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| EP4321519A3 (en) * | 2018-10-12 | 2024-05-01 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP1038880B1 (en) * | 1994-02-14 | 2007-10-17 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of GABA receptor |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| NZ298567A (en) | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| SG11201504848QA (en) | 2012-12-18 | 2015-07-30 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| TW202426002A (zh) * | 2014-10-16 | 2024-07-01 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
| MA51315A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter des troubles du snc |
| MA51316A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter les troubles du snc |
| WO2019154257A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| EP4321519A3 (en) * | 2018-10-12 | 2024-05-01 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| TWI896548B (zh) | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| MX2021015848A (es) * | 2019-06-27 | 2022-04-18 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del snc. |
| CN115551874A (zh) | 2020-03-18 | 2022-12-30 | 萨奇治疗股份有限公司 | 神经活性类固醇及其使用方法 |
| IL299176A (en) | 2020-06-24 | 2023-02-01 | Sage Therapeutics Inc | Neuroactive steroids converted to 3.alpha.-hydroxy, 17.beta.-C-(O)-N-aryl and their compounds |
-
2019
- 2019-10-11 EP EP23197779.4A patent/EP4321519A3/en active Pending
- 2019-10-11 AU AU2019357040A patent/AU2019357040B2/en active Active
- 2019-10-11 JP JP2021519712A patent/JP7671244B2/ja active Active
- 2019-10-11 CN CN202511082220.8A patent/CN121045302A/zh active Pending
- 2019-10-11 WO PCT/US2019/055926 patent/WO2020077255A1/en not_active Ceased
- 2019-10-11 EP EP19797472.8A patent/EP3864022B1/en active Active
- 2019-10-11 US US17/284,206 patent/US11634453B2/en active Active
- 2019-10-11 BR BR112021009428-8A patent/BR112021009428A2/pt unknown
- 2019-10-11 CN CN201980079330.5A patent/CN113166193B/zh active Active
- 2019-10-11 AR ARP190102913A patent/AR116695A1/es unknown
- 2019-10-11 DK DK19797472.8T patent/DK3864022T3/da active
- 2019-10-11 MX MX2021004159A patent/MX2021004159A/es unknown
- 2019-10-11 CA CA3115805A patent/CA3115805A1/en active Pending
- 2019-10-11 ES ES19797472T patent/ES2966055T3/es active Active
- 2019-10-14 TW TW113106814A patent/TWI886813B/zh active
- 2019-10-14 TW TW108136955A patent/TWI835884B/zh active
-
2021
- 2021-04-08 IL IL282183A patent/IL282183A/en unknown
- 2021-04-09 MX MX2024011494A patent/MX2024011494A/es unknown
-
2023
- 2023-02-21 US US18/171,798 patent/US20240376144A9/en active Pending
-
2024
- 2024-02-14 JP JP2024020461A patent/JP2024040444A/ja active Pending
-
2025
- 2025-01-22 AU AU2025200422A patent/AU2025200422A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021004159A (es) | 2021-09-08 |
| IL282183A (en) | 2021-05-31 |
| EP4321519A2 (en) | 2024-02-14 |
| BR112021009428A2 (pt) | 2021-08-31 |
| US11634453B2 (en) | 2023-04-25 |
| AU2019357040A1 (en) | 2021-05-20 |
| AU2025200422A1 (en) | 2025-02-13 |
| CA3115805A1 (en) | 2020-04-16 |
| MX2024011494A (es) | 2024-09-26 |
| US20240051987A1 (en) | 2024-02-15 |
| EP3864022A1 (en) | 2021-08-18 |
| JP2024040444A (ja) | 2024-03-25 |
| DK3864022T3 (da) | 2023-12-18 |
| US20240376144A9 (en) | 2024-11-14 |
| TW202448479A (zh) | 2024-12-16 |
| CN113166193B (zh) | 2025-08-19 |
| TWI886813B (zh) | 2025-06-11 |
| AU2019357040B2 (en) | 2025-03-27 |
| EP3864022B1 (en) | 2023-09-20 |
| WO2020077255A1 (en) | 2020-04-16 |
| JP7671244B2 (ja) | 2025-05-01 |
| EP4321519A3 (en) | 2024-05-01 |
| CN121045302A (zh) | 2025-12-02 |
| JP2022504607A (ja) | 2022-01-13 |
| TW202027753A (zh) | 2020-08-01 |
| ES2966055T3 (es) | 2024-04-18 |
| CN113166193A (zh) | 2021-07-23 |
| TWI835884B (zh) | 2024-03-21 |
| US20210340172A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116695A1 (es) | Los neuroesteroides y sus métodos de uso | |
| AR117264A1 (es) | Esteroides neuroactivos y métodos para su uso | |
| AR119047A1 (es) | Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc | |
| AR119305A1 (es) | Composiciones y métodos para el tratamiento de los trastornos del snc | |
| AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
| AR120896A1 (es) | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz | |
| AR121609A1 (es) | Esteroides neuroactivos y sus métodos de uso | |
| AR113765A1 (es) | Inhibidores de la proteasa del vih | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR090191A1 (es) | Derivados del acido fenil alcanoico como agonistas gpr | |
| AR120697A1 (es) | Inhibidores de braf como rompedores de la paradoja | |
| AR115085A1 (es) | DERIVADOS DE 3-AMINO-2,4,6-TRIAZINA COMO INHIBIDORES DE LA TIROSINA CINASA DE BRUTON (Btk) | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| ES2639407T3 (es) | Derivados de cianoquinolina | |
| AR116905A1 (es) | Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor | |
| AR121745A1 (es) | MODULADORES DE a-1 ANTITRIPSINA | |
| AR120865A1 (es) | Tieniloxazolonas y análogos utilizados en el control de enfermedades de plantas | |
| AR113811A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR131158A1 (es) | Compuestos que inhiben la pkmyt1 | |
| AR120864A1 (es) | Tiofenocarboxamidas sustituidas y sus derivados | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| AR116906A1 (es) | Derivados de heteroarilo bicíclico | |
| AR119344A1 (es) | Carboxamidas de tiofeno sustituidas y derivados de estas para el control de microorganismos fitopatógenos | |
| AR125365A1 (es) | Derivados de 1h-pirazol como ligandos sigma |